Deborah K. Armstrong
A5090143508- Ovarian cancer diagnosis and treatment
- Intraperitoneal and Appendiceal Malignancies
- PARP inhibition in cancer therapy
- Toxin Mechanisms and Immunotoxins
- BRCA gene mutations in cancer
- Endometrial and Cervical Cancer Treatments
- Plant tissue culture and regeneration
- Cancer Risks and Factors
- Medicinal Plants and Bioactive Compounds
- Renal cell carcinoma treatment
- DNA Repair Mechanisms
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Breast Cancer Treatment Studies
- Cancer, Lipids, and Metabolism
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Reproductive Biology and Fertility
- Endometriosis Research and Treatment
- Cancer therapeutics and mechanisms
- Diet and metabolism studies
- Lymphoma Diagnosis and Treatment
- Dietary Effects on Health
- Cancer survivorship and care
- Epigenetics and DNA Methylation
Johns Hopkins University
2016-2025
Sidney Kimmel Cancer Center
2014-2025
Cancer Research Center
2025
Sidney Kimmel Comprehensive Cancer Center
2015-2024
Johns Hopkins Medicine
2014-2024
Johns Hopkins Hospital
2013-2023
United States Nuclear Regulatory Commission
2023
California State University, Dominguez Hills
2023
Middle Tennessee State University
2023
Jones College
2023
The genomes of cancers deficient in mismatch repair contain exceptionally high numbers somatic mutations. In a proof-of-concept study, we previously showed that colorectal with deficiency were sensitive to immune checkpoint blockade antibodies programmed death receptor-1 (PD-1). We have now expanded this study evaluate the efficacy PD-1 patients advanced repair-deficient across 12 different tumor types. Objective radiographic responses observed 53% patients, and complete achieved 21%...
Standard chemotherapy for newly diagnosed ovarian cancer is a platinum-taxane combination. The Gynecologic Oncology Group conducted randomized, phase 3 trial that compared intravenous paclitaxel plus cisplatin with intraperitoneal and in patients stage III cancer.We randomly assigned carcinoma or primary peritoneal no residual mass greater than 1.0 cm to receive 135 mg of per square meter body-surface area over 24-hour period followed by either 75 on day 2 (intravenous-therapy group) 100 60...
Purpose Conflicting results on prognostic factors for advanced epithelial ovarian cancer (EOC) have been reported because of small sample size and heterogeneity study population. The purpose this was to identify predictive poor prognosis in a similarly treated population women with EOC. Patients Methods A retrospective review demographic, pathologic, treatment, outcome data from 1,895 patients International Federation Gynecology Obstetrics stage III EOC who had undergone primary surgery...
Purpose We evaluated the efficacy and safety of bevacizumab in patients with platinum-resistant epithelial ovarian carcinoma (EOC) or peritoneal serous (PSC) who had experienced disease progression during, within 3 months discontinuing, topotecan liposomal doxorubicin. Patients Methods No more than three prior treatment regimens were allowed. received single-agent 15 mg/kg intravenously every weeks. Response was assessed by computed tomography (CT) scan 6 weeks using Evaluation Criteria...
Epithelial ovarian cancer is the most lethal of gynecologic malignancies, largely due to advanced stage at diagnosis in patients. Screening strategies using ultrasound and antigen (CA) 125 tumor marker are currently under study may lower but have not yet been shown improve survival. Women who inherited a deleterious mutation BRCA1 or BRCA2 gene those with Lynch syndrome (hereditary nonpolyposis colorectal cancer) highest risk developing account for only approximately 10% disease. Other less...
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States and country’s fifth most common mortality women. A major challenge treating that patients have advanced disease at initial diagnosis. These NCCN Guidelines discuss cancers originating ovary, fallopian tube, or peritoneum, as these are all managed a similar manner. Most recommendations based on data with subtypes─high-grade serous grade 2/3 endometrioid. The also include specifically for less cancers,...
Purpose: To prospectively determine cancer yield, callback and biopsy rates, positive predictive value (PPV) of mammography, magnetic resonance (MR) imaging, ultrasonography (US) in women at high risk for breast cancer. Materials Methods: The study was approved by the institutional review board HIPAA compliant, informed consent obtained. We conducted a prospective pilot screening MR, US asymptomatic 25 years age or older who were genetically risk, defined as BRCA1/BRCA2 carriers with least...
To provide guidance to clinicians regarding the use of neoadjuvant chemotherapy and interval cytoreduction among women with stage IIIC or IV epithelial ovarian cancer.
This selection from the NCCN Guidelines for Ovarian Cancer focuses on less common ovarian histopathologies (LCOHs), because new algorithms were added LCOHs and current revised 2016 update. The include clear cell carcinomas, mucinous grade 1 (low-grade) serous carcinomas/endometrioid epithelial carcinomas. also carcinosarcomas (malignant mixed Müllerian tumors of ovary), borderline (also known as low malignant potential tumors), sex cord-stromal tumors, germ tumors.
Secondary surgical cytoreduction in women with platinum-sensitive, recurrent epithelial ovarian, primary peritoneal, or fallopian-tube ("ovarian") cancer is widely practiced but has not been evaluated phase 3 investigation.
Purpose To determine long-term survival and associated prognostic factors after intraperitoneal (IP) chemotherapy in patients with advanced ovarian cancer. Patients Methods Data from Gynecologic Oncology Group protocols 114 172 were retrospectively analyzed. Cox proportional hazards regression models used for statistical analyses. Results In 876 patients, median follow-up was 10.7 years. Median IP therapy 61.8 months (95% CI, 55.5 to 69.5), compared 51.4 46.0 58.2) intravenous therapy. a 23%...
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States, with less than half patients living >5 years diagnosis. A major challenge treating that most have advanced disease at initial The best outcomes are observed whose primary treatment includes complete resection all visible plus combination platinum-based chemotherapy. Research efforts focused on neoadjuvant treatments may improve resectability, as well systemic therapies providing improved long-term...
Epithelial ovarian cancer is the leading cause of death from gynecologic in United States, with less than half patients living >5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations diagnosis, evaluation, treatment, and follow-up ovarian, fallopian tube, primary peritoneal cancers. These Insights summarize panel discussion behind recent important updates to guidelines, including revised guidance on alternative chemotherapy regimens advanced age and/or...
PURPOSE BRAF V600 mutations are commonly found in melanoma and thyroid cancers to a lesser degree other tumor types. Subprotocol H (EAY131-H) of the NCI-MATCH platform trial sought investigate selective inhibitor dabrafenib MEK1/2 trametinib patients with solid tumors, lymphomas, or multiple myeloma whose tumors harbored mutation. PATIENTS AND METHODS EAY131-H is an open-label, single-arm study. Patients melanoma, thyroid, colorectal cancer were excluded; non–small-cell lung later excluded...
Using murine myeloid factor-dependent FDC-P1/ER cells, we demonstrate that the hematopoietic growth factors interleukin-3 and erythropoietin bryostatin-1, a macrocyclic lactone natural product potent activator of protein kinase C (PKC), suppress apoptosis induce rapid serine phosphorylation Bc12 alpha. Expression recombinant wild type alpha in NFS/N1.H-7 cells confirms is phosphorylated following PKC activation. The inhibitors H-7 staurosporine, but not A inhibitor HA1004, block only...
Purpose To assess the pharmacogenomic and pharmacokinetic determinants of skin rash diarrhea, two primary dose-limiting toxicities epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor erlotinib. Patients Methods A prospective clinical study 80 patients with non–small-cell lung cancer, head neck ovarian cancer was performed. Detailed pharmacokinetics toxicity erlotinib were assessed. Polymorphic loci in EGFR, ABCG2, CYP3A4, CYP3A5 genotyped, their effects on evaluated. Results...